{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"DCB is defined as the time from the date of first documentation of a minimal response or better to the date of first documentation of confirmed progressive disease or death due to any cause, whichever occurs first. DCB will be calculated for only participants who achieved a minimal response or better. DCB will be assessed by the investigator as per IMWG criteria.","groups":[{"description":"Participants were planned to receive modakafusp alfa at dose level 1 (DL1) \\[selected from Phase 1 Dose Escalation\\] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.","id":"OG000","title":"Phase 2a Dose Finding: Modakafusp Alfa (DL1) + Daratumumab"},{"description":"Participants were planned to receive modakafusp alfa at dose level 2 (DL2) \\[selected from Phase 1 Dose Escalation\\] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.","id":"OG001","title":"Phase 2a Dose Finding: Modakafusp Alfa (DL2) + Daratumumab"}],"populationDescription":"After completion of Phase 1 Dose Escalation of this study the sponsor decided not to proceed with Phase 2a due to strategic reasons (no safety concerns). Thus, no participants were enrolled for Phase 2a \\& no data was collected for this outcome measure due to study termination.","reportingStatus":"POSTED","timeFrame":"Phase 2a: Up to 15.9 months","title":"Phase 2a: Duration of Clinical Benefit (DCB)","type":"SECONDARY"}